On the stock market since 2020, it operates in the world of health and science. It has 2,700 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executives buying with their own money is usually read as confidence in the company’s future.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Cost Efficiency: As sales grow, profit fails to keep the same pace.
An investor who bought at the very peak is down 94% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The company sells $965.4M a year; the problem isn’t sales — it’s costs running above that number.
Over the last 12 months, company executives reported 18 buys and 1 sell. Management buying with its own money is usually read as a good sign.
A loss of $284.3M against $965.4M in annual sales.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
The stock trades 57% above the average analyst price target.
On our five-subject report card, MPLN sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: MPLN has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.